Matthew brings decades of expertise to the fight against inherited retinal diseases, with a career focused on precision medicine and human genetics. His work spans multiple therapeutic areas including: immunology, metabolic disorders and neurodegeneration. At Octant, he leads efforts to translate cutting-edge discoveries into therapies that address unmet medical needs in rare diseases like autosomal dominant retinitis pigmentosa (adRP) and Fabry Disease.

Before joining Octant, Matthew served as Chief Translational Officer at Human Immunology Biosciences and Senior Vice President at insitro, where he directed the Department of Translational Genetics and Biology. At Genentech, he founded and led the Reverse Translation Organization within the Cancer Immunology Department, leading efforts to bridge clinical insights back into drug discovery. He also served as Director of the Immunology Department at the Institut Pasteur in Paris, where he co-founded the Milieu Intérieur Consortium, a global initiative to uncover the genetic, microbiome and environmental determinants of health and disease.

Matthew’s work resulted in the discovery of multiple drug targets and advancement of numerous therapies into clinical trials and clinical practice. His foundational research provided definitive evidence that human tumor immunity is driven by the cross-priming of antigen-specific cytotoxic T cells (CD8+), laying the groundwork for modern immuno-oncology treatments.

Matthew holds an M.D. from Weill Cornell Medical College, a Ph.D. in Immunology from Rockefeller University, and completed his residency in Clinical Pathology at New York Presbyterian Hospital. He is committed to translating scientific breakthroughs into real-world impact, working with patient communities to ensure that innovative therapies address their needs and improve their lives.

Outside of Octant, Matthew enjoys spending quality time with his wife and daughter, as well as cycling, backcountry skiing and cooking.